Clinical Trials Browser

OTHER × Triple Negative Breast Neoplasms × navitoclax × Clear all

NCT05358639 2024-11-18

Combination of Olaparib and Navitoclax in Women with HGSC and TNBC

Phase 1 Active not recruiting

BreastGynecologic

Ovarian Neoplasms, Triple Negative Breast Neoplasms